Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study.

Front Endocrinol (Lausanne) · 2021 · PMC8059833 · PMID 33897615

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Nominally significant mean improvements were seen in both patient subgroups for other key secondary endpoints, including reductions in total cholesterol, LDL-cholesterol, body weight, and BMI ( Table 3 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.